Osborne Clarke has advised Creo Medical Group plc on the acquisition of Albyn Medical for an equity value of €24.8m.
The agreement also included a performance-related payment of up to €2.7m, payable over the next two years in cash.
The acquisition provides Creo with Albyn Medical’s extensive sales, service, logistics, production and export capability, providing a direct route-to-market for Creo’s full suite of CE marked GI advanced energy devices. It also adds a highly complementary product range to the company’s portfolio while expanding the GI product suite and providing an opportunity for it to enter the urology market.
Albyn Medical specialises in GI endoscopy and urology with commercial relationships with doctors and hospitals across key European territories. The company’s GI products account for 90% of sales with 10% of revenues derived from urology products.
A team of lawyers from across Osborne Clarke’s international business advised Creo. In Spain, Partner David Miranda (Picture) led the team alongside Lawyers Sara Barona and Pilar Díaz. In the UK, the team was led by Partner David Ferris with support from Senior Associate Ashley Morris and Associate Rebecca Ewing. Partner David Haccoun and Associate Cyrille d’Amécourt from Osborne Clarke in Paris, and Partner Martin Sundermann and Senior Associate Enno Dreier from Osborne Clarke in Germany also advised.
Involved fees earner: Sara Barona – Osborne Clarke; Pilar Díaz – Osborne Clarke; Enno Dreier – Osborne Clarke; Cyrille d’Amécourt – Osborne Clarke; Rebecca Ewing – Osborne Clarke; David Ferris – Osborne Clarke; David Haccoun – Osborne Clarke; David Miranda – Osborne Clarke; Ashley Morris – Osborne Clarke; Martin Sundermann – Osborne Clarke;
Law Firms: Osborne Clarke;
Clients: Creo Medical Group;